Therapeutic Advances in Medical Oncology
@tamedoncol.bsky.social
A SAGE Publishing Gold #openaccess journal | Publishing innovative clinically focused articles on the medical treatment of cancer| PubMed Indexed | IF: 4.3
We’re proud to see our Associate Editor, Prof. Nadia Harbeck, contributing to the upcoming #ESMOYOC YO4YO HowTo session on career crossroads in oncology. Don’t miss it! 📅 25 Nov, 15:00 CET. #YoungOncologists
Get ready for the next YO4YO HowTo Virtual session with Ana Tecic Vuger, Nadia Harbeck and Kevin Punie MD #YoungOncologists #ESMOYOC
📌 Career Crossroads in #Oncology: Clinical, #research, and #leadership journeys
📅 25 November 2025
🕒 15:00–16:00 CET
🔗 https://ow.ly/R7MJ50XpRy1
📌 Career Crossroads in #Oncology: Clinical, #research, and #leadership journeys
📅 25 November 2025
🕒 15:00–16:00 CET
🔗 https://ow.ly/R7MJ50XpRy1
November 17, 2025 at 8:44 AM
We’re proud to see our Associate Editor, Prof. Nadia Harbeck, contributing to the upcoming #ESMOYOC YO4YO HowTo session on career crossroads in oncology. Don’t miss it! 📅 25 Nov, 15:00 CET. #YoungOncologists
🔬 CDK4/6 inhibitors have transformed HR+ MBC care - but resistance is a growing challenge.
This review explores the molecular drivers and emerging strategies to counteract them. Full article 👉 buff.ly/1YracNB #CancerResearch #Oncology
This review explores the molecular drivers and emerging strategies to counteract them. Full article 👉 buff.ly/1YracNB #CancerResearch #Oncology
November 17, 2025 at 8:15 AM
🔬 CDK4/6 inhibitors have transformed HR+ MBC care - but resistance is a growing challenge.
This review explores the molecular drivers and emerging strategies to counteract them. Full article 👉 buff.ly/1YracNB #CancerResearch #Oncology
This review explores the molecular drivers and emerging strategies to counteract them. Full article 👉 buff.ly/1YracNB #CancerResearch #Oncology
Reposted by Therapeutic Advances in Medical Oncology
Kicking off #SIBCS2025 in Shanghai! Proud to represent Sage Publishing as Editor of Therapeutic Advances in Medical Oncology and Co-Editor of Clinical Medicine Insights: Oncology + Rare Tumors.
Come say hi at booth #29! 🧬📚 #BreastCancer #Oncology #MedicalResearch
Come say hi at booth #29! 🧬📚 #BreastCancer #Oncology #MedicalResearch
November 14, 2025 at 2:36 AM
Kicking off #SIBCS2025 in Shanghai! Proud to represent Sage Publishing as Editor of Therapeutic Advances in Medical Oncology and Co-Editor of Clinical Medicine Insights: Oncology + Rare Tumors.
Come say hi at booth #29! 🧬📚 #BreastCancer #Oncology #MedicalResearch
Come say hi at booth #29! 🧬📚 #BreastCancer #Oncology #MedicalResearch
🔬 New insights into HER2-low TNBC: • 47.7% of Asian TNBC patients classified as HER2-low • Distinct genomic profile (↓ BRCA1, ↑ PIK3CA) • No difference in survival outcomes vs HER2-zero
Full study 👉 buff.ly/kXKMwn8 #BreastCancer #HER2 #CancerResearch
Full study 👉 buff.ly/kXKMwn8 #BreastCancer #HER2 #CancerResearch
November 13, 2025 at 8:15 AM
🔬 New insights into HER2-low TNBC: • 47.7% of Asian TNBC patients classified as HER2-low • Distinct genomic profile (↓ BRCA1, ↑ PIK3CA) • No difference in survival outcomes vs HER2-zero
Full study 👉 buff.ly/kXKMwn8 #BreastCancer #HER2 #CancerResearch
Full study 👉 buff.ly/kXKMwn8 #BreastCancer #HER2 #CancerResearch
Could the clock be a treatment factor? This retrospective study of 248 patients with mGC found better survival outcomes when nivolumab was infused before mid-afternoon.
Authors suggest infusion timing should be considered in daily practice. Details here: buff.ly/k54we7o
Authors suggest infusion timing should be considered in daily practice. Details here: buff.ly/k54we7o
November 10, 2025 at 9:21 AM
Could the clock be a treatment factor? This retrospective study of 248 patients with mGC found better survival outcomes when nivolumab was infused before mid-afternoon.
Authors suggest infusion timing should be considered in daily practice. Details here: buff.ly/k54we7o
Authors suggest infusion timing should be considered in daily practice. Details here: buff.ly/k54we7o
🧬 Immunotherapy has transformed cancer care-but #prostatecancer remains resistant.
This review explores why traditional approaches fall short and highlights emerging strategies like: Checkpoint inhibitors; T-cell engagers; CAR-T cells
buff.ly/OV5DpZ2
#ProstateCancer #Immunotherapy #Oncology #CAR_T
This review explores why traditional approaches fall short and highlights emerging strategies like: Checkpoint inhibitors; T-cell engagers; CAR-T cells
buff.ly/OV5DpZ2
#ProstateCancer #Immunotherapy #Oncology #CAR_T
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
November 7, 2025 at 8:15 AM
🧬 Immunotherapy has transformed cancer care-but #prostatecancer remains resistant.
This review explores why traditional approaches fall short and highlights emerging strategies like: Checkpoint inhibitors; T-cell engagers; CAR-T cells
buff.ly/OV5DpZ2
#ProstateCancer #Immunotherapy #Oncology #CAR_T
This review explores why traditional approaches fall short and highlights emerging strategies like: Checkpoint inhibitors; T-cell engagers; CAR-T cells
buff.ly/OV5DpZ2
#ProstateCancer #Immunotherapy #Oncology #CAR_T
🏠Can indoor radon affect lung cancer mutations? The RADON EUROPE study shows a link between high radon levels (>400 Bq/m³) and ALK rearrangements in NSCLC across 21 European countries.📍 This emphasizes the need for studying environmental impacts on cancer genomics. buff.ly/C3ktYC5 #LungCancer #NSCLC
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
November 5, 2025 at 8:15 AM
🏠Can indoor radon affect lung cancer mutations? The RADON EUROPE study shows a link between high radon levels (>400 Bq/m³) and ALK rearrangements in NSCLC across 21 European countries.📍 This emphasizes the need for studying environmental impacts on cancer genomics. buff.ly/C3ktYC5 #LungCancer #NSCLC
📢 Study on advanced #PancreaticCancer treatment reveals key survival factors: Only 8.3% of 204 patients lived beyond 2 years. ✅ Longer survival linked to good physical function (PS 0), low CRP & CA 19-9, high albumin, and peritoneal metastasis without fluid buildup.
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
November 3, 2025 at 8:15 AM
📢 Study on advanced #PancreaticCancer treatment reveals key survival factors: Only 8.3% of 204 patients lived beyond 2 years. ✅ Longer survival linked to good physical function (PS 0), low CRP & CA 19-9, high albumin, and peritoneal metastasis without fluid buildup.
📢 Call for Papers!
Submit to our special issue: “Geriatric Oncology: Advancing Cancer Care in an Aging World” buff.ly/ASkDwOt
🗓️ Join the conversation on cancer care for older adults.
#GeriatricOncology #CancerResearch #Oncology #CallForPapers #MedicalPublishing
Submit to our special issue: “Geriatric Oncology: Advancing Cancer Care in an Aging World” buff.ly/ASkDwOt
🗓️ Join the conversation on cancer care for older adults.
#GeriatricOncology #CancerResearch #Oncology #CallForPapers #MedicalPublishing
November 1, 2025 at 7:15 AM
📢 Call for Papers!
Submit to our special issue: “Geriatric Oncology: Advancing Cancer Care in an Aging World” buff.ly/ASkDwOt
🗓️ Join the conversation on cancer care for older adults.
#GeriatricOncology #CancerResearch #Oncology #CallForPapers #MedicalPublishing
Submit to our special issue: “Geriatric Oncology: Advancing Cancer Care in an Aging World” buff.ly/ASkDwOt
🗓️ Join the conversation on cancer care for older adults.
#GeriatricOncology #CancerResearch #Oncology #CallForPapers #MedicalPublishing
Adding anti-angiogenesis therapy to PD-1/PD-L1 + chemo improves PFS and ORR in ES-SCLC, especially in patients under 65. No OS benefit overall. Safety comparable.
🔗 buff.ly/tMshYDZ
#LungCancer #CheckpointInhibitors #MetaAnalysis
🔗 buff.ly/tMshYDZ
#LungCancer #CheckpointInhibitors #MetaAnalysis
Efficacy and safety of first-line PD-1/PD-L1 inhibitors combined with or without anti-angiogenesis therapy for extensive-stage small-cell lung cancer: a network meta-analysis - Linjing Zhou, Yuwei Li, Le Wang, Kaiyan Chen, Shichao Zhou, Yunfei Chen, Jing Sun, Yunfeng Tong, Yun Fan, 2025
Background: Immune checkpoint inhibitors (ICIs) combined with chemotherapy, with or without angiogenesis inhibitors, have been investigated as the first-line tr...
doi.org
October 31, 2025 at 7:15 AM
Adding anti-angiogenesis therapy to PD-1/PD-L1 + chemo improves PFS and ORR in ES-SCLC, especially in patients under 65. No OS benefit overall. Safety comparable.
🔗 buff.ly/tMshYDZ
#LungCancer #CheckpointInhibitors #MetaAnalysis
🔗 buff.ly/tMshYDZ
#LungCancer #CheckpointInhibitors #MetaAnalysis
PD-1/PD-L1 inhibitors show promise in HBV-related hepatocellular carcinoma. Patients with low HBV DNA and early qHBsAg response had longer survival. Viral biomarkers could shape future immunotherapy strategies. buff.ly/ciwROOE
#LiverCancer #HBV #CheckpointInhibitors
#LiverCancer #HBV #CheckpointInhibitors
Relationship between HBsAg/HBV DNA and prognosis in patients with HBV-related hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors - Qiuying Qin, Yuanyuan Zheng, Yiran Wang, Fei Zhou, Dong Li, Linlin Jin, Mujia Zhu, Yabing Guo, Rong Fan, Jinlin Hou, Xiaoyong Zhang, Hongyan Liu, 2025
Objectives: Blocking the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) axis could reverse the immune tolerance in the liver microenviron...
journals.sagepub.com
October 29, 2025 at 7:15 AM
PD-1/PD-L1 inhibitors show promise in HBV-related hepatocellular carcinoma. Patients with low HBV DNA and early qHBsAg response had longer survival. Viral biomarkers could shape future immunotherapy strategies. buff.ly/ciwROOE
#LiverCancer #HBV #CheckpointInhibitors
#LiverCancer #HBV #CheckpointInhibitors
Pregnancy after BC is not only possible - it’s often safe. But young survivors need tailored, multidisciplinary support to navigate fertility, treatment, and long-term health. More research is needed on novel agents like CDK4/6 and PARP inhibitors. buff.ly/l10yF3b #OncoFertility #BreastCancer
Pregnancy after breast cancer: latest evidence and practical considerations - Nadia Mordenfeld Kozlovsky, Ann H. Partridge, Tal Sella, 2025
Advancements in breast cancer care have significantly improved survival rates in women of all ages; however, young survivors face unique challenges related to f...
journals.sagepub.com
October 27, 2025 at 7:15 AM
Pregnancy after BC is not only possible - it’s often safe. But young survivors need tailored, multidisciplinary support to navigate fertility, treatment, and long-term health. More research is needed on novel agents like CDK4/6 and PARP inhibitors. buff.ly/l10yF3b #OncoFertility #BreastCancer
🧠 New real-world data on HER2-positive MIBC suggests limited benefit from adjuvant chemo or targeted therapy.
With a 5-year DFS of 95.1%, this @tamedoncol.bsky.social study raises important questions about treatment necessity
🔗 buff.ly/HBeagpd
#BreastCancer #HER2 #OncologyResearch
With a 5-year DFS of 95.1%, this @tamedoncol.bsky.social study raises important questions about treatment necessity
🔗 buff.ly/HBeagpd
#BreastCancer #HER2 #OncologyResearch
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
October 24, 2025 at 7:15 AM
🧠 New real-world data on HER2-positive MIBC suggests limited benefit from adjuvant chemo or targeted therapy.
With a 5-year DFS of 95.1%, this @tamedoncol.bsky.social study raises important questions about treatment necessity
🔗 buff.ly/HBeagpd
#BreastCancer #HER2 #OncologyResearch
With a 5-year DFS of 95.1%, this @tamedoncol.bsky.social study raises important questions about treatment necessity
🔗 buff.ly/HBeagpd
#BreastCancer #HER2 #OncologyResearch
Precision matters.
A new @tamedoncol.bsky.social review dives into the evolving landscape of non-clear cell RCC, emphasizing molecular profiling, novel targets, and the 2022 WHO reclassification.
Read more: buff.ly/5jyCunC
#RenalCellCarcinoma #nccRCC #TargetedTherapy
A new @tamedoncol.bsky.social review dives into the evolving landscape of non-clear cell RCC, emphasizing molecular profiling, novel targets, and the 2022 WHO reclassification.
Read more: buff.ly/5jyCunC
#RenalCellCarcinoma #nccRCC #TargetedTherapy
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
buff.ly
October 22, 2025 at 7:15 AM
Precision matters.
A new @tamedoncol.bsky.social review dives into the evolving landscape of non-clear cell RCC, emphasizing molecular profiling, novel targets, and the 2022 WHO reclassification.
Read more: buff.ly/5jyCunC
#RenalCellCarcinoma #nccRCC #TargetedTherapy
A new @tamedoncol.bsky.social review dives into the evolving landscape of non-clear cell RCC, emphasizing molecular profiling, novel targets, and the 2022 WHO reclassification.
Read more: buff.ly/5jyCunC
#RenalCellCarcinoma #nccRCC #TargetedTherapy
🚀 The future of #GastricCancer therapy may lie beyond traditional oncogenic targets.
Explore how Claudin18.2, Nectin-4, and Caprin-1 are opening new doors for precision oncology in this @tamedoncol.bsky.social review.
🔗 journals.sagepub.com/doi/full/10....
#OncologyResearch #ESMO25 #CancerTherapy
Explore how Claudin18.2, Nectin-4, and Caprin-1 are opening new doors for precision oncology in this @tamedoncol.bsky.social review.
🔗 journals.sagepub.com/doi/full/10....
#OncologyResearch #ESMO25 #CancerTherapy
Emerging evidence of targeting non-oncogenic drivers for gastric cancer: Claudin18.2 and beyond - Kazumasa Yamamoto, Izuma Nakayama, Kohei Shitara, 2025
Human epidermal growth factor receptor 2 was the first successful molecular target in treating gastric cancer, marking a significant milestone for targeted ther...
journals.sagepub.com
October 20, 2025 at 7:15 AM
🚀 The future of #GastricCancer therapy may lie beyond traditional oncogenic targets.
Explore how Claudin18.2, Nectin-4, and Caprin-1 are opening new doors for precision oncology in this @tamedoncol.bsky.social review.
🔗 journals.sagepub.com/doi/full/10....
#OncologyResearch #ESMO25 #CancerTherapy
Explore how Claudin18.2, Nectin-4, and Caprin-1 are opening new doors for precision oncology in this @tamedoncol.bsky.social review.
🔗 journals.sagepub.com/doi/full/10....
#OncologyResearch #ESMO25 #CancerTherapy
🎉 Honoring excellence in oncology!
Huge congratulations to our Associate Editor Dr. Natasha Leighl on receiving the #ESMO25 Women for Oncology Award.
A true leader in advancing cancer care and inspiring the next generation of researchers.
#WomenInSTEM #OncologyLeadership #lungcancer
Huge congratulations to our Associate Editor Dr. Natasha Leighl on receiving the #ESMO25 Women for Oncology Award.
A true leader in advancing cancer care and inspiring the next generation of researchers.
#WomenInSTEM #OncologyLeadership #lungcancer
Natasha Leighl, recipient of the 2025 ESMO Women for Oncology Award, will present her Award lecture at the #ESMO25 Opening Session. She will discuss key contributions to #LungCancer research & the role of liquid biopsy in #CancerDiagnostics.
📅 Opening Session https://ow.ly/BwMO50XavIS
📅 Opening Session https://ow.ly/BwMO50XavIS
October 17, 2025 at 5:10 AM
🎉 Honoring excellence in oncology!
Huge congratulations to our Associate Editor Dr. Natasha Leighl on receiving the #ESMO25 Women for Oncology Award.
A true leader in advancing cancer care and inspiring the next generation of researchers.
#WomenInSTEM #OncologyLeadership #lungcancer
Huge congratulations to our Associate Editor Dr. Natasha Leighl on receiving the #ESMO25 Women for Oncology Award.
A true leader in advancing cancer care and inspiring the next generation of researchers.
#WomenInSTEM #OncologyLeadership #lungcancer
In non-metastatic HER2− #BreastCancer, NCDB data (2018) showed higher pCR rates with neoadjuvant chemo in HR-Low vs HR-High groups. HR-Low tumors had higher grade/stage and lower endocrine therapy use, underscoring need for clearer treatment guidance.
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
October 10, 2025 at 3:59 PM
In non-metastatic HER2− #BreastCancer, NCDB data (2018) showed higher pCR rates with neoadjuvant chemo in HR-Low vs HR-High groups. HR-Low tumors had higher grade/stage and lower endocrine therapy use, underscoring need for clearer treatment guidance.
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
In HR+ advanced #BreastCancer progressing after CDK4/6 inhibitors, network meta-analysis (19 RCTs; n=6621) found CDK4/6i + fulvestrant most effective for PFS, especially in visceral metastases or ESR1 mutations; Bcl-2i + Ful and SERDs also showed benefit
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
October 10, 2025 at 3:57 PM
In HR+ advanced #BreastCancer progressing after CDK4/6 inhibitors, network meta-analysis (19 RCTs; n=6621) found CDK4/6i + fulvestrant most effective for PFS, especially in visceral metastases or ESR1 mutations; Bcl-2i + Ful and SERDs also showed benefit
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
In HER2+ salivary duct carcinoma, trastuzumab-deruxtecan (T-Dxd) achieved 13 months of disease control in a multitreated 44-year-old patient, supporting further study of anti-HER2 therapy in rare salivary tumors.
🔗 journals.sagepub.com/doi/epdf/10....
#HER2 #SalivaryCancer #Oncology
🔗 journals.sagepub.com/doi/epdf/10....
#HER2 #SalivaryCancer #Oncology
October 10, 2025 at 3:54 PM
In HER2+ salivary duct carcinoma, trastuzumab-deruxtecan (T-Dxd) achieved 13 months of disease control in a multitreated 44-year-old patient, supporting further study of anti-HER2 therapy in rare salivary tumors.
🔗 journals.sagepub.com/doi/epdf/10....
#HER2 #SalivaryCancer #Oncology
🔗 journals.sagepub.com/doi/epdf/10....
#HER2 #SalivaryCancer #Oncology
In HER2-mutated non-small-cell lung cancer, combination regimens achieved markedly better outcomes than single-agent approaches.
Median PFS: 7.8 vs 5.3 mo; best results seen with chemo + immunotherapy + anti-angiogenic therapy.
🔗 journals.sagepub.com/doi/epdf/10....
Median PFS: 7.8 vs 5.3 mo; best results seen with chemo + immunotherapy + anti-angiogenic therapy.
🔗 journals.sagepub.com/doi/epdf/10....
October 10, 2025 at 3:51 PM
In HER2-mutated non-small-cell lung cancer, combination regimens achieved markedly better outcomes than single-agent approaches.
Median PFS: 7.8 vs 5.3 mo; best results seen with chemo + immunotherapy + anti-angiogenic therapy.
🔗 journals.sagepub.com/doi/epdf/10....
Median PFS: 7.8 vs 5.3 mo; best results seen with chemo + immunotherapy + anti-angiogenic therapy.
🔗 journals.sagepub.com/doi/epdf/10....
In patients with metastatic #gastriccancer, earlier nivolumab monotherapy infusions (before 14:00) were associated with significantly longer PFS and OS (7.6 vs 3.9 mo). Authors suggest infusion timing may influence outcomes in #Immunotherapy practice.
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
October 10, 2025 at 3:48 PM
In patients with metastatic #gastriccancer, earlier nivolumab monotherapy infusions (before 14:00) were associated with significantly longer PFS and OS (7.6 vs 3.9 mo). Authors suggest infusion timing may influence outcomes in #Immunotherapy practice.
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
Reposted by Therapeutic Advances in Medical Oncology
🚨 Call for Papers – Special Collection! @tamedoncol.bsky.social seeks submissions on: De-escalation of Treatment in Gynecologic Cancers. 🗓️ Submit by March 18, 2026 📥 Submit:
buff.ly
October 10, 2025 at 7:15 AM
🚨 Call for Papers – Special Collection! @tamedoncol.bsky.social seeks submissions on: De-escalation of Treatment in Gynecologic Cancers. 🗓️ Submit by March 18, 2026 📥 Submit:
Ontario study of OHIP data (2015–2022): female cancer diagnostic billing dropped in 2020 (cervical −50.7/100k, breast −13.9/100k) but rebounded sharply in 2021–22, with net excesses across all cancer types. COVID-19 disruptions drove delayed diagnoses.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
October 3, 2025 at 2:53 PM
Ontario study of OHIP data (2015–2022): female cancer diagnostic billing dropped in 2020 (cervical −50.7/100k, breast −13.9/100k) but rebounded sharply in 2021–22, with net excesses across all cancer types. COVID-19 disruptions drove delayed diagnoses.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
Phase III FLINTER trial (N=317) shows rituximab biosimilar DRL_RI is equivalent to MabThera® in untreated low–tumor-burden follicular lymphoma: BORR 80.2% vs 79.4% (Δ0.9%, CI within ±17%). Safety, immunogenicity, PK/PD profiles comparable. #Lymphoma
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
October 3, 2025 at 2:52 PM
Phase III FLINTER trial (N=317) shows rituximab biosimilar DRL_RI is equivalent to MabThera® in untreated low–tumor-burden follicular lymphoma: BORR 80.2% vs 79.4% (Δ0.9%, CI within ±17%). Safety, immunogenicity, PK/PD profiles comparable. #Lymphoma
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
Study of 2896 early-stage #BreastCancer pts: CanAssist Breast prognostic test stratified ER1–20% subgroup. 65% classified low risk with 91% DRFI, 35% high risk with 61% DRFI. CAB may guide tailored therapy beyond ER levels in this challenging group.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
October 3, 2025 at 2:50 PM
Study of 2896 early-stage #BreastCancer pts: CanAssist Breast prognostic test stratified ER1–20% subgroup. 65% classified low risk with 91% DRFI, 35% high risk with 61% DRFI. CAB may guide tailored therapy beyond ER levels in this challenging group.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....